CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
CG Oncology (NASDAQ: CGON) announced its participation in the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain, from March 21-24, 2025. The company will present multiple studies on cretostimogene grenadenorepvec, their bladder-sparing therapeutic for bladder cancer.
Key presentations include:
- Late-breaking clinical and first translational data from BOND-003 Cohort C, presented by Dr. Trinity J. Bivalacqua
- Translational correlates using urinary genomic disease burden analysis from BOND-003 and CORE-001 trials, presented by Dr. Sharada Mokkapati
- BOND-003 cohort P study results for high-risk, papillary BCG-unresponsive cases
- PIVOT-006 phase 3 randomized study of adjuvant treatment versus surveillance for intermediate-risk cases
CG Oncology (NASDAQ: CGON) ha annunciato la sua partecipazione al 40° Congresso Annuale dell'Associazione Europea di Urologia (EAU) che si terrà a Madrid, Spagna, dal 21 al 24 marzo 2025. L'azienda presenterà diversi studi su cretostimogene grenadenorepvec, la loro terapia che preserva la vescica per il cancro alla vescica.
Le presentazioni chiave includono:
- Dati clinici in ritardo e primi dati traslazionali dal BOND-003 Coorte C, presentati dal Dr. Trinity J. Bivalacqua
- Correlati traslazionali utilizzando l'analisi del carico di malattia genomica urinaria dai trial BOND-003 e CORE-001, presentati dal Dr. Sharada Mokkapati
- Risultati dello studio della coorte P di BOND-003 per casi ad alto rischio, papillari e non responsivi al BCG
- Studio randomizzato di fase 3 PIVOT-006 di trattamento adiuvante rispetto alla sorveglianza per casi a rischio intermedio
CG Oncology (NASDAQ: CGON) anunció su participación en el 40º Congreso Anual de la Asociación Europea de Urología (EAU) en Madrid, España, del 21 al 24 de marzo de 2025. La compañía presentará múltiples estudios sobre cretostimogene grenadenorepvec, su tratamiento que preserva la vejiga para el cáncer de vejiga.
Las presentaciones clave incluyen:
- Datos clínicos de última hora y primeros datos traslacionales del BOND-003 Cohorte C, presentados por el Dr. Trinity J. Bivalacqua
- Correlatos traslacionales utilizando análisis del carga de enfermedad genómica urinaria de los ensayos BOND-003 y CORE-001, presentados por la Dra. Sharada Mokkapati
- Resultados del estudio de la cohorte P de BOND-003 para casos de alto riesgo, papilares y no responsivos al BCG
- Estudio aleatorizado de fase 3 PIVOT-006 de tratamiento adyuvante versus vigilancia para casos de riesgo intermedio
CG Oncology (NASDAQ: CGON)는 2025년 3월 21일부터 24일까지 스페인 마드리드에서 열리는 제40회 유럽 비뇨기학회(EAU) 연례 회의에 참여한다고 발표했습니다. 이 회사는 방광암 치료를 위한 방광 보존 치료제인 cretostimogene grenadenorepvec에 대한 여러 연구를 발표할 예정입니다.
주요 발표 내용은 다음과 같습니다:
- Dr. Trinity J. Bivalacqua가 발표하는 BOND-003 코호트 C의 최신 임상 데이터 및 첫 번째 전이 데이터
- Dr. Sharada Mokkapati가 발표하는 BOND-003 및 CORE-001 시험의 요로 유전체 질병 부담 분석을 통한 전이적 상관관계
- BCG에 반응하지 않는 고위험 유두형 BOND-003 코호트 P 연구 결과
- 중간 위험 사례에 대한 보조 치료와 감시를 비교한 PIVOT-006 3상 무작위 연구
CG Oncology (NASDAQ: CGON) a annoncé sa participation au 40ème Congrès Annuel de l'Association Européenne d'Urologie (EAU) à Madrid, Espagne, du 21 au 24 mars 2025. L'entreprise présentera plusieurs études sur cretostimogene grenadenorepvec, leur traitement préservant la vessie pour le cancer de la vessie.
Les présentations clés comprennent:
- Données cliniques de dernière minute et premières données translationnelles de la cohorte C de BOND-003, présentées par le Dr Trinity J. Bivalacqua
- Corrélats translationnels utilisant l'analyse de la charge de maladie génomique urinaire des essais BOND-003 et CORE-001, présentés par le Dr Sharada Mokkapati
- Résultats de l'étude de la cohorte P de BOND-003 pour des cas à haut risque, papillaires et non réactifs au BCG
- Étude randomisée de phase 3 PIVOT-006 du traitement adjuvant par rapport à la surveillance pour des cas à risque intermédiaire
CG Oncology (NASDAQ: CGON) gab seine Teilnahme am 40. Jahreskongress der Europäischen Urologie Gesellschaft (EAU) in Madrid, Spanien, vom 21. bis 24. März 2025 bekannt. Das Unternehmen wird mehrere Studien zu cretostimogene grenadenorepvec, ihrer blasen-sparenden Therapie für Blasenkrebs, präsentieren.
Wichtige Präsentationen umfassen:
- Aktuelle klinische Daten und erste translationale Daten aus der BOND-003 Kohorte C, präsentiert von Dr. Trinity J. Bivalacqua
- Translationale Korrelate unter Verwendung der Analyse der genomischen Krankheitslast im Urin aus den Studien BOND-003 und CORE-001, präsentiert von Dr. Sharada Mokkapati
- Ergebnisse der BOND-003 Kohorte P Studie für hochriskante, papilläres BCG-unempfindliche Fälle
- PIVOT-006 Phase 3 randomisierte Studie zur adjuvanten Behandlung im Vergleich zur Überwachung für Fälle mit mittlerem Risiko
- None.
- None.
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be presented at the 40th Annual European Association of Urology (EAU) Congress taking place in Madrid, Spain, from March 21-24, 2025. The Annual EAU Congress is Europe’s biggest urological event, where thousands of healthcare professionals from around the world gather to present research and learn about the latest innovations in patient care.
CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including:
Late Breaking Abstract Number: LB12
Session: Abstract Session 45 - NMIBC: Innovations and outcomes 1
Presenter: Trinity J. Bivalacqua, M.D., Professor of Urology and Oncology at the Perelman Center for Advanced Medicine, University of Pennsylvania, Division of Urology and the Director of Urology Oncology and GU Service Line in the Cancer Center.
Presentation Date & Time: March 24, 2025, 10:45 - 12:15 CET
Location: Pink Area N101, Ifema, Madrid
Translational correlates using urinary genomic disease burden to assess cretostimogene grenadenorepvec: Analysis from the BOND-003 and CORE-001 trials
Abstract Number: A0793
Session: Abstract Session 45 - NMIBC: Innovations and outcomes 1
Presenter: Sharada Mokkapati, Ph.D., Basic Science Faculty, Department of Urology, University of Texas MD Anderson Cancer Center
Presentation Date & Time: March 24, 2025, 10:45 - 12:15 CET
Location: Pink Area N101, Ifema, Madrid
BOND-003 cohort P - a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer
Abstract Number: A0083
Session: Abstract Session 05 - On the horizon: Ongoing trials in urology
Presenter: Siamak Daneshmand, M.D., Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center
Presentation Date & Time: March 21, 2025, 15:15 - 16:45 CET
Location: Green Area Retiro, Ifema, Madrid
PIVOT-006 - a phase 3, randomized study of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance for the treatment of intermediate-risk non-muscle invasive bladder cancer
Abstract Number: A0082
Session: Abstract Session 05 - On the horizon: Ongoing trials in urology
Presenter: Siamak Daneshmand, M.D., Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center
Presentation Date & Time: March 21, 2025, 15:15 - 16:45 CET
Location: Green Area Retiro, Ifema, Madrid
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in patients with intermediate-risk NMIBC. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
What will CG Oncology present at the 2025 EAU Congress regarding BOND-003 Cohort C?
When and where will CGON's presentations take place at the EAU Congress 2025?
What is the PIVOT-006 study that CGON will present at EAU 2025?
How many presentations will CGON deliver at the 2025 EAU Congress?
